Coronary collateral circulation and mortality in ST-elevation myocardial infarction undergoing primary PCI: an updated systematic review and meta-analysis of 18,443 patients

冠状动脉侧支循环与接受直接经皮冠状动脉介入治疗(PCI)的ST段抬高型心肌梗死患者的死亡率:一项纳入18443例患者的最新系统评价和荟萃分析

阅读:5

Abstract

BACKGROUND: Coronary collateral circulation may limit myocardial injury during ST-elevation myocardial infarction (STEMI), but the magnitude of this association with mortality in contemporary practice remains unclear. We conducted an updated meta-analysis to reassess the relationship between collateral status and mortality in STEMI patients undergoing primary percutaneous coronary intervention (PCI). METHODS: We searched PubMed, Embase, and Scopus (March 2020–January 2026) to update the meta-analysis by Allahwala et al. Studies comparing mortality between robust versus poor collaterals were included. Random-effects meta-analysis was performed. RESULTS: Twenty-six studies comprising 18,443 patients were included (19 studies from the original meta-analysis plus 7 new studies). In the primary analysis of 17 studies using standard Rentrop definitions (15,493 patients), robust collaterals were associated with significantly lower mortality (OR 0.52; 95% CI 0.39–0.71; p < 0.0001; I²=38%). This corresponded to an absolute risk reduction of 2.7%. Importantly, the 3 new studies showed attenuated effects (OR 0.88; 95% CI 0.49–1.58) compared to the 14 original studies (OR 0.47; p = 0.06 for subgroup difference). Meta-regression identified higher baseline mortality as a predictor of larger effect sizes (p = 0.038). The certainty of evidence was LOW (GRADE). CONCLUSIONS: Robust coronary collaterals are associated with lower mortality in STEMI patients undergoing primary PCI. However, the apparent attenuated association in contemporary studies likely reflects statistical dilution due to lower baseline mortality rather than diminished biological relevance of collaterals. Given the LOW certainty of evidence from observational data, collateral assessment should be considered prognostic rather than a basis for interventions. REVIEW REGISTRATION: (PROSPERO Registration ID: CRD420261278634) CLINICAL TRIAL NUMBER: Not Applicable (As this is a Systematic Review and Meta-Analysis and not a clinical trial). GRAPHICAL ABSTRACT: [Figure: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12872-026-05740-w.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。